Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 6Phase 1 6Phase 3 1

Status

Completed 3Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available 1Lung Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 626pembrolizumab 505Paclitaxel 456Gemcitabine 439Carboplatin 437Cisplatin 420Radiotherapy 382fludarabine 367Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 245Fluorouracil 229Dexamethasone 225Specimen Handling 223Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Ipilimumab 198Temozolomide 197Biopsy 197fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × tepotinib × Clear all
NCT07619339 2026-06-02

A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
16 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05782361 2026-04-24

POTENT

Institute of Cancer Research, United Kingdom

Phase 1 Active not recruiting
19 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05120960 2024-04-17

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

M.D. Anderson Cancer Center

Phase 1 Withdrawn
CNS

Brain Neoplasms

NCT03492437 2023-08-07

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
20 enrolled 14 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03531762 2023-07-28

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
12 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01014936 2022-08-24

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

EMD Serono

Phase 1 Completed
149 enrolled 41 charts
Other solid neoplasm

Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available

Data powered by HemOnc (CC BY 4.0) Colophon âš¡